Hyperuricemia Hyperuricemia, Atrial fibrillation, Arteriosclerosis, Endothelial dysfunction
Conditions
Interventions
Drug administration for hyperuricemia
Sponsors
Okada Kozo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years of age or older 2. Patients with serum uric acid levels >7 mg/dL or currently taking urate-lowering medication 3. Patients who have undergone ablation therapy for atrial fibrillation and are maintaining sinus rhythm 4. Participants who have received sufficient explanation about the study content and have provided written consent
Exclusion criteria
Exclusion criteria: 1. Patients with concurrent active malignant tumors. 2. Patients whose acute gouty arthritis has not subsided 3. Patients currently suffering from urinary tract stones 4. Patients with known secondary hyperuricemia meeting the following criteria: Lesch-Nyhan syndrome, phosphoribosyl pyrophosphate synthetase overproduction syndrome, congenital myogenic hyperuricemia, hematologic malignancies (acute leukemia, malignant lymphoma, myeloproliferative disorders, myelodysplastic syndromes), solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer), non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia), tumor lysis syndrome, rhabdomyolysis, hypothyroidism, polycystic kidney disease, lead poisoning/lead nephropathy, Down syndrome, familial juvenile gouty nephropathy, hyperlactatemia, type I glycogen storage disease 5. Patients receiving mercaptopurine hydrate or azathioprine 6. Patients with severe hepatic impairment (Child-Pugh class C or higher) 7. Patients with severe renal impairment (eGFR < 20) presenting with oliguria or anuria, and dialysis patients 8. Patients who are pregnant, may become pregnant, or are breastfeeding 9. Patients with hypersensitivity to dothienure or febuxostat components 10. Patients for whom CAVI measurement is difficult 11. Patients deemed unsuitable for this study by the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change rate of CAVI from baseline to week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in serum uric acid levels and percentage change at 4, 8, 12, and 24 weeks after drug administration 2. Proportion of patients achieving serum uric acid levels 30 seconds detected by Holter ECG or captured on a 12-lead ECG, 2. Use of antiarrhythmic drugs, 3. Re-ablation | — |
Contacts
Public ContactHisaya Kondo
Division of Cardiology, Yokohama City University Medical Center
Outcome results
None listed